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Abstract
Aim: To assess the efficacy of oral NEPA (netupitant‐palonosetron 300/0.50 mg) 
over multiple chemotherapy cycles.
Methods: Two randomized phase III studies evaluated a single dose of oral NEPA 
given on day 1 in chemotherapy‐naive patients receiving anthracycline‐cyclophos-
phamide (AC)–based (Study 1) or highly (HEC)/moderately (MEC) emetogenic 
chemotherapy (safety Study 2). Oral NEPA was compared with oral palonosetron 
0.50 mg (Study 1) or oral aprepitant 125 mg day 1, 80 mg days 2‐3/palonosetron 
0.50 mg (Study 2; no formal statistical comparisons). Oral dexamethasone was 
administered in all treatment groups. Complete response (CR; no emesis/no rescue 
medication), no emesis, and no significant nausea (NSN) rates during acute (0‐24 h) 
and delayed (>24‐120 h) phases of chemotherapy cycles 1‐4 in each study were 
evaluated.
Results: In Study 1, 1450 patients received 5969 chemotherapy cycles; in Study 2, 
412 patients received 1961 chemotherapy cycles. In each study, ≥75% of patients 
completed 4 or more cycles. In Study 1, oral NEPA was superior to palonosetron in 
preventing chemotherapy‐induced nausea and vomiting (CINV) in the acute and 
delayed phases of cycle 1, with higher rates of CR (all P < 0.05), no emesis (all 
P < 0.05), and NSN (delayed phase P < 0.05 cycles 1, 2, and 4) reported across 4 
cycles. In Study 2, oral NEPA had numerically higher CR and NSN rates in the acute 
and delayed phases than aprepitant‐palonosetron in MEC/HEC patients.
Conclusion: Oral NEPA was highly effective in preventing both acute and delayed 
CINV over multiple chemotherapy cycles of HEC, AC, and MEC regimens.
Clinical trial registration numbers: Study 1, NCT01339260; Study 2, 
NCT01376297.
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1 |  INTRODUCTION
Chemotherapy‐induced nausea and vomiting (CINV) is 
a debilitating complication and one of multiple adverse 
events frequently reported in patients receiving routine 
chemotherapy. If poorly controlled, CINV impairs quality 
of life1 and may compromise anticancer treatment adher-
ence (reviewed in Hesketh2). Nausea and vomiting belong to 
a cluster of symptoms that if correctly managed, may lead 
to longer survival.3,4 CINV is primarily mediated through 
neurotransmitters, such as serotonin, substance P, and dopa-
mine,5 and can be categorized into acute (0‐24 h) and delayed 
phases (>24‐ 120 h).2 Acute CINV results mainly from sero-
tonin's action on the 5‐hydroxytryptamine‐3 (5‐HT3) recep-
tor, while delayed CINV is mainly mediated by substance P 
acting on the neurokinin‐1 (NK1) receptor.6
Delayed CINV occurs more frequently than acute 
CINV,1,7 and is experienced by over 50% of patients receiving 
chemotherapy, despite antiemetic prophylaxis use.1,7 It 
tends to be underreported by patients, and the incidence is 
underestimated by most oncology physicians and nurses.7-9
For effective antiemetic prophylaxis, control throughout 
the entire period of emetic risk in the first and subsequent 
chemotherapy cycles is necessary.10 If CINV is inadequately 
controlled in the first cycle, it may become more difficult to 
manage,11 with a 14% increased risk of CINV in subsequent 
cycles.12 Controlling CINV over multiple cycles with an NK1 
receptor antagonist (RA) has been shown to reduce resource 
utilization, particularly by preventing delayed CINV.13,14 
Prevention of CINV from the first cycle therefore remains 
the main goal for successful CINV control.
Current antiemetic guidelines of the National 
Comprehensive Cancer Network (NCCN)15 and the 
Multinational Association of Supportive Care in Cancer 
(MASCC)/European Society for Medical Oncology (ESMO)16 
recommend the triplet combination of an NK1 RA, a 5‐HT3 
RA, and dexamethasone (DEX) to prevent CINV in patients 
receiving highly emetogenic chemotherapy (HEC).15-17 
The American Society of Clinical Oncology (ASCO) and 
NCCN endorse the addition of olanzapine to this triplet in 
patients receiving HEC and before the start of chemotherapy, 
with additional prophylaxis (DEX and olanzapine) on days 
2‐4 of chemotherapy; NK1 RA aprepitant (APR) is part of 
the prophylaxis on days 2‐3 if given on day 1.15,17 For patients 
receiving moderately emetogenic chemotherapy (MEC), a 
5‐HT3 RA in combination with DEX on day 1 is generally ad-
vised,15-17 with the addition of an NK1 RA for certain patients 
with additional risk factors or previous treatment failure 
when receiving a steroid plus 5‐HT3 RA alone15; additional 
prophylaxis may be offered on days 2 and 3 of chemother-
apy if necessary.15,17 MASCC/ESMO first introduced a new 
recommendation for adding an NK1 RA to the 5‐HT3 RA plus 
DEX regimen for patients receiving carboplatin, regardless of 
dose.16 The NCCN and ASCO guidelines now also make the 
same recommendation for carboplatin area under the curve 
(AUC) ≥4 mg mL−1 min.15,17 Only the NCCN guidelines 
have reclassified carboplatin AUC ≥4 mg mL−1 min from a 
MEC to a HEC agent.15
Oral NEPA is the first and only antiemetic combina-
tion agent; it is composed of netupitant (300 mg), a highly 
selective NK1 RA, and the pharmacologically18 and clini-
cally19 distinct 5‐HT3 RA palonosetron (PALO, 0.50 mg). 
NEPA thereby antagonizes 2 key neurotransmitters involved 
in the pathophysiology of CINV, and provides acute and 
delayed CINV control with a single dose. Real‐world evi-
dence suggests complicated antiemetic schedules are often 
not followed by patients, leading to mistakes/missed doses 
of prophylactic agents prescribed to be taken over multiple 
days.5 The convenient administration schedule of oral NEPA 
may therefore enable improved adherence to the antiemetic 
regimen and guidelines. Oral NEPA has been shown to be 
superior to oral PALO in preventing CINV during the acute, 
delayed, and overall phases following the first cycle of 
cisplatin‐based20 or anthracycline‐cyclophosphamide (AC)‐
based chemotherapy.21 Oral NEPA is well tolerated, with a 
safety profile consistent with the NK1 RA and 5‐HT3 RA 
classes.20,21 An intravenous (IV) formulation of the NEPA 
fixed combination has been developed to offer clinicians and 
patients further convenience, and IV NEPA plus DEX was 
recently approved by the US Food and Drug Administration 
for the prevention of CINV in patients receiving HEC, with a 
limitation of use in AC‐based chemotherapy.22 A phase IIIb 
study evaluating the safety of IV NEPA in patients receiving 
AC‐based chemotherapy is ongoing.
Two phase III studies, evaluating the efficacy and safety 
of oral NEPA over multiple cycles of chemotherapy, form the 
basis of this report.21,23,24 In both studies, previously published 
data demonstrated that oral NEPA maintained antiemetic 
control during the 5‐day period following chemotherapy 
(overall phase) over at least 4 cycles of chemotherapy.23,24 
Oral NEPA also showed superior complete response (CR) 
rates compared with oral PALO during the overall phase in 
cycle 1, and the difference was statistically significant over 
repeated cycles.23 At the time both trials were conducted, 
MEC included AC‐based regimens in patients with breast 
cancer (referred to herein as AC MEC). However, AC‐based 
K E Y W O R D S
CINV, delayed phase, efficacy, multiple cycles, NEPA, netupitant
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chemotherapy has since been reclassified as HEC.15-17 For 
consistency with the original publications of each trial, pa-
tients are referred to as receiving AC MEC in Study 121 and 
HEC or non‐AC MEC in Study 2 (breast cancer patients 
scheduled to receive AC‐based chemotherapy in Study 2 
were not eligible).24 This report focuses on the efficacy of 
oral NEPA during the acute and delayed phases over 4 cycles 
of chemotherapy in these studies.
2 |  METHODS
2.1 | Studies
Two international, randomized, double‐blind phase 
III trials, Study 1 (NCT01339260)21 and Study 2 
(NCT01376297),24 were analyzed. Both evaluated the 
efficacy of oral NEPA in patients with solid tumors, 
including patients diagnosed with any malignant tumor in 
Study 2. Detailed study designs, methods, and eligibility 
criteria have been reported previously and are summa-
rized in Figure 1.21,24 Oral DEX was open‐label and the 
dosing schedule was based on the emetogenicity of the 
chemotherapy according to the antiemetic guidelines valid 
at the time the studies were performed.25 Both study proto-
cols were approved by the relevant ethical review commit-
tees, all patients provided written informed consent, and 
all investigators and site personnel followed International 
Conference on Harmonization E6 Good Clinical Practice 
guidelines, Declaration of Helsinki (2008) ethical princi-
ples, and local laws and regulations.
2.2 | Assessments
CR (defined as no emesis and no rescue medication) and no 
significant nausea (NSN; defined as a score of <25 mm on 
a visual analog scale of 100 mm) were assessed during the 
acute and delayed phases after chemotherapy initiation, for 
the first 4 cycles; “no emesis” was also collected in Study 1.
F I G U R E  1  Schemas of 2 international, randomized, double‐blind phase III trials: Study 1 (NCT01339260)21 and Study 2 (NCT01376297).24 
a3:1 randomization NEPA: APR + PALO; the protocol also specified that 75% of patients would receive MEC and 25% HEC. AC, anthracycline‐ 
cyclophosphamide; APR, aprepitant; DEX, dexamethasone; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; 
NEPA, netupitant‐palonosetron; NETU, netupitant; PALO, palonosetron
Study 1: Patients with solid tumors receiving an AC regimen
Study 2: Patients with solid tumors receiving a HEC or non-AC MEC regimen
Randomized
1:1
Oral NEPA
(NETU 300 mg
PALO 0.50 mg)
Oral PALO 
0.50 mg
Cycle 1 day 1
60 min before 
chemotherapy
30 min before 
chemotherapy
Multiple-cycle 
extension, 
provided inclusion 
criteria continue 
to be met
DEX 20 mg
DEX 12 mg 
Randomized
3:1a
Oral NEPA
(NETU 300 mg
PALO 0.50 mg)
HEC: DEX 12 mg HEC: DEX 8 mg days 2–4
MEC: DEX not given
Administered 
in morning
Multiple-cycle 
extension, 
provided inclusion 
criteria continue 
to be met
30 min before 
chemotherapy
MEC: DEX 12 mg
HEC: DEX 12 mg
HEC: APR 80 mg days 2–3 
DEX 8 mg days 2–4
MEC: APR 80 mg days 2–3;
DEX not given
MEC: DEX 12 mg
Oral APR 125 mg + 
PALO 0.50 mg
Cycle 1 day 1 Cycle 1 days 2–4
60 min before 
chemotherapy
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2.3 | Statistical considerations
Efficacy data were not pooled across the 2 studies because of 
different study objectives, designs, chemotherapy regimens, 
and populations. All efficacy analyses were undertaken on 
the full analysis set (defined as all randomized patients who 
received chemotherapy and study drug). In Study 1, CR, no 
emesis, and NSN rates for the oral NEPA and oral PALO arms 
were compared using a 2‐sided Cochran‐Mantel‐Haenszel 
test stratified by age class (<55 years, ≥55 years) and region 
(US, Latin America, Europe, Commonwealth of Independent 
States, and Asia) for all 4 cycles; this test was the same used 
at cycle 1 for the primary and key secondary efficacy analyses 
as per prespecified study plan. For cycles 2‐4, a formal 
statistical comparison was not prespecified; no method to 
adjust for multiplicity was applied. No formal comparisons 
of efficacy were made between the oral NEPA and oral APR‐
PALO arms in Study 2, as its primary endpoint was safety. 
CR and NSN rates are also reported separately for the subsets 
of NEPA patients receiving either MEC or HEC; APR‐PALO 
data are not included for these chemotherapy subsets since 
the small sample size (considering the 3:1 randomization 
ratio) hindered interpretation, especially for repeated cycles. 
As most patients completed their planned therapy after 4 
treatment cycles, efficacy data are presented over only cycles 
1‐4 (safety data have been previously published21).
3 |  RESULTS
3.1 | Analyzed patient population
In total, 1455 patients were randomized in Study 1: 726 
to oral NEPA and 729 to oral PALO (Table 1). Of these, 
1450 patients (99.7%) were treated for a total of 5969 
chemotherapy cycles; 1438 patients (98.8%) completed cycle 
1, and 1286 patients (88.4%) entered the multiple‐cycle ex-
tension 23; 1107 patients (76.1%) completed 4 or more cycles. 
Most patients completed their planned chemotherapy after 4 
treatment cycles; 35.7% of patients received a fifth cycle, and 
26.7% received a sixth cycle (data not shown).
In Study 2, 413 patients were randomized: 309 to oral NEPA 
and 104 to oral APR‐PALO (Table 1). Of these, 412 patients 
(99.8%) were treated for a total of 1961 chemotherapy cycles; 
405 patients (98.1%) completed cycle 1, 311 patients (75.3%) 
completed 4 or more cycles; 51.6% of patients received a fifth 
cycle, and 40.0% received a sixth cycle (data not shown).
Baseline and disease characteristics from both studies 
are reported in Table 2. These characteristics remained con-
sistent across cycles, and were similar between treatment 
arms. In Study 1, the median age was 54 years, 98.1% 
of patients were female, and 97.4% had breast cancer. In 
Study 2, the median age was 58 years, 50% of patients were 
female, and the most prevalent cancer was lung/respira-
tory cancer (37.4%). Per protocol, most patients (75.7%) 
received MEC (Table 3).
3.2 | Efficacy
3.2.1 | Study 1
Oral NEPA was superior to oral PALO in preventing 
CINV in the acute and delayed phases in cycle 1 (Table 3, 
Figure 2A), with high rates of control maintained in sub-
sequent cycles. In the oral NEPA group, CR rates ranged 
from 88.4% to 91.6%, and 76.9% to 85.5% for the acute 
and delayed phases, respectively, across 4 cycles. These 
T A B L E  1  Summary of patient disposition from Study 1 and Study 2—all randomized patients
Study 1a Study 2b 
NEPA 
(N = 726) 
(C = 2983)
PALO 
(N = 729) 
(C = 2986)
Overall 
(N = 1455) 
(C = 5969)
NEPA 
(N = 309) 
(C = 1446)
APR‐PALO 
(N = 104) 
(C = 515)
Overall 
(N = 413) 
(C = 1961)
Treated, n (%) 724 (99.7) 726 (99.6) 1450 (99.7) 309 (100.0) 103 (99.0) 412 (99.8)
Completed 
cycle 1, n (%)
719 (99.0) 719 (98.6) 1438 (98.8) 303 (98.1) 102 (98.1) 405 (98.1)
Completed 
cycle 2, n (%)
630 (86.8) 645 (88.5) 1275 (87.6) 278 (90.0) 94 (90.4) 372 (90.1)
Completed 
cycle 3, n (%)
596 (82.1) 603 (82.7) 1199 (82.4) 255 (82.5) 88 (84.6) 343 (83.1)
Completed 
cycle 4, n (%)
548 (75.5) 559 (76.7) 1107 (76.1) 230 (74.4) 81 (77.9) 311 (75.3)
C = Total number of cycles started for all treated patients.
APR, aprepitant; NEPA, netupitant‐palonosetron; PALO, palonosetron.
aData corresponding to cycles 5‐8 not shown. 
bData corresponding to cycles 5‐14 not shown. 
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rates were higher and differences were statistically signifi-
cant compared with the PALO group (between‐group com-
parisons for individual cycles, all P < 0.05 not adjusted 
for multiplicity). Likewise, higher rates of NSN and no 
emesis were observed for oral NEPA versus oral PALO 
(Table 4). In the oral NEPA group, the rates of no emesis 
across 4 cycles ranged from 90.9% to 93.1%, and 81.8% 
to 89.5% for the acute and delayed phases, respectively, 
and differences were statistically significant compared 
with the PALO‐treatment group (between‐group compar-
isons for individual cycles, all P < 0.05 not adjusted for 
multiplicity). In the oral NEPA group, the rates of NSN 
across 4 cycles ranged from 87.3% to 91.3%, and 76.9% to 
81.7% for the acute and delayed phases, respectively; dif-
ferences were statistically significant in the delayed‐phase 
NSN rates compared with the PALO group (between‐group 
comparisons for individual cycles, P < 0.05 for cycles 1, 2, 
and 4 not adjusted for multiplicity).
3.2.2 | Study 2
In Study 2, the CR rates were high across cycles 1‐4 for both 
treatment groups. In patients treated with oral NEPA, CR rates 
ranged from 92.9% to 96.6%, and 83.2% to 91.5% for the acute 
T A B L E  2  Baseline and disease characteristics of patients from Study 1 and Study 2—safety population (cycle 1)
Study 1 Study 2
NEPA 
(N = 725)
PALO 
(N = 725)
Overall 
(N = 1450)
NEPA 
(N = 308)
APR‐PALO 
(N = 104)
Overall 
(N = 412)
Gender, %
Male 1.9 1.9 1.9 49.7 51.0 50.0
Female 98.1 98.1 98.1 50.3 49.0 50.0
Median age, years 54.0 54.0 54.0 57.0 58.5 58.0
Cancer type, %
Breast 97.7 97.2 97.4 12.7 8.7 11.7
Lung/respiratory — — — 39.6 30.8 37.4
Ovarian — — — 10.7 17.3 12.4
Head and neck — — — 6.5 10.6 7.5
Colorectal — — — 16.2 22.1 17.7
Gastric — — — 2.3 1.0 1.9
Bladder — — — 1.3 2.9 1.7
Othera 2.3 2.8 2.6 16.7 6.7 9.7
Extent of cancer at entry, %
Primary 81.8 82.9 82.3 43.8 51.9 45.9
Metastatic 16.3 15.6 15.9 51.9 43.3 49.8
Local recurrence 1.9 1.5 1.7 4.2 4.8 4.4
Site of metastasis, %
Lymph nodes 10.8 11.7 11.2 33.1 21.2 30.1
Other 5.5 3.2 4.3 15.6 19.2 16.5
Liver 2.9 2.1 2.5 12.0 12.5 12.1
Bone 3.7 3.6 3.7 5.8 4.8 5.6
Brain 0.3 0 0.1 1.6 2.9 1.9
ECOG performance 
status, %
1 69.5 69.2 69.4 47.4 48.1 47.6
2 29.7 30.6 30.1 51.0 50.0 50.7
3 0.8 0.1 0.5 1.6 1.9 1.7
APR, aprepitant; ECOG, Eastern Cooperative Oncology Group; NEPA, netupitant‐palonosetron; PALO, palonosetron.
aThe category “other” included any other type of cancer not listed in the prespecified categories, including, but not limited to, those of the uterus, larynx, and 
endometrium. 
   | 2069SCHWARTZBERG ET Al.
and delayed phases, respectively. These rates were similar but 
numerically higher compared with oral APR‐PALO, except 
for acute CR and acute NSN in cycle 1 (Table 4, Figure 2B). 
Similar results were seen in the subsets of NEPA patients 
receiving MEC (n = 235 at cycle 1). Across cycles 1‐4, CR 
rates of 93.2%, 97.2%, 96.4%, and 97.2% were observed in 
the acute phase, and 81.7%, 88.7%, 90.8%, and 91.7% in 
the delayed phase. For APR‐PALO patients receiving MEC 
(n = 77 at cycle 1), CR rates of 93.5%, 94.6%, 97.3%, and 
97.0% were observed across cycles 1‐4 in the acute phase, and 
84.4%, 85.1%, 87.8%, and 88.1% in the delayed phase (data 
not shown). For the subset of NEPA patients receiving HEC 
(n = 74 at cycle 1), CR rates of 91.9%, 94.1%, 95.2%, and 
94.2% were reported across cycles 1‐4 in the acute phase, and 
87.8%, 80.9%, 93.7%, and 88.5% in the delayed phase. For 
APR‐PALO patients receiving HEC (n = 26 at cycle 1), CR 
rates of 96.2%, 81.8%, 87.5%, and 92.9% were reported across 
cycles 1‐4 in the acute phase, and 57.7%, 72.7%, 87.5%, and 
85.7% in the delayed phase (data not shown).
NSN rates were also high in both treatment groups, with 
numerically higher rates for NEPA compared with APR‐
PALO. Across cycles 1‐4, NEPA‐treated patients had NSN 
rates ranging from 90.6% to 97.0%, and 85.1% to 91.8% in 
the acute and delayed phases, respectively (Table 4).
4 |  DISCUSSION
This report presents the efficacy results of 2 pivotal trials 
evaluating the safety and efficacy of oral NEPA in the acute 
and delayed phases over multiple chemotherapy cycles in 
patients with solid tumors (in Study 2, patients with any ma-
lignant tumor were eligible). In Study 1, superiority of NEPA 
to PALO in preventing CINV in the acute, delayed, and over-
all phases during cycle 1 of AC‐based chemotherapy was 
clearly demonstrated,21 with overall CR sustained across mul-
tiple cycles23 (overall CR for oral NEPA was 74.3%–83.8% 
across 4 cycles; overall no emesis and NSN rates for oral 
NEPA were 79.8%–88.3% and 74.6%–80.2%, respectively, all 
across 4 cycles [Table 3]). The current analysis now reports 
higher response rates with NEPA, compared with PALO, for 
all 3 efficacy measures (CR, NSN, and no emesis) during the 
acute and delayed phases across all 4 chemotherapy cycles 
(P < 0.05 not adjusted for multiplicity). In the previously 
T A B L E  3  Chemotherapy received in patients from Study 1 and Study 2—safety population (cycle 1)
Study 1 chemotherapya , % NEPA (N = 725) PALO (N = 725)
Overall 
(N = 1450)
ACb 
Doxorubicin 68.0 63.6 65.8
Cyclophosphamide 99.9 99.9 99.9
Epirubicin 32.0 36.3 34.2
Study 2 chemotherapya , % NEPA (N = 308) APR‐PALO (N = 104)
Overall 
(N = 412)
MECc 75.7 75.7 75.7
Carboplatin 60.3 61.5 60.6
Oxaliplatin 20.1 24.4 21.2
Doxorubicind 11.1 6.4 9.9
Cyclophosphamided 3.4 2.6 3.2
Irinotecan 3.0 3.8 3.2
Epirubicind 1.7 1.3 1.6
Daunorubicin 0.4 0 0.3
HECc 24.3 24.3 24.3
Cisplatin 96.0 92.0 95.0
Dacarbazine 4.0 4.0 4.0
Carmustine 0 4.0 1.0
AC, anthracycline‐cyclophosphamide; APR, aprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; NEPA, netupitant‐ 
palonosetron, PALO: palonosetron.
aPercentages are based on efficacy (full analysis) population, while all others are based on safety population (cycle 1). 
bBreast cancer patients scheduled to receive AC‐based chemotherapy in Study 2 were not eligible. 
cCycle 1 chemotherapy. 
dCyclophosphamide and doxorubicin or epirubicin were administered together as “AC” in Study 1. 
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reported results of Study 2, the safety and efficacy with NEPA 
were maintained, and NEPA resulted in numerically higher 
overall CR rates than APR‐PALO in cycle 1 and subsequent 
cycles24 (overall CR for oral NEPA was 80.6%–90.7% across 
4 cycles; overall NSN for oral NEPA was 84.1%–91.8% 
across 4 cycles [Table 3]). This current analysis also found 
CR and NSN rates were numerically higher for NEPA in the 
acute and delayed phases for both the overall population and 
the MEC and HEC subgroups.
Collectively, these data show the efficacy of oral NEPA in 
preventing CINV, particularly in the delayed phase in cycle 
1; this was maintained over multiple cycles. NK1 RA regi-
mens have historically been studied primarily in cisplatin‐
based HEC and AC settings, so these data expand the known 
efficacy of NEPA, ergo NK1 RA regimens, to MEC regi-
mens as well. These findings are thus rellevant to a broad 
range of chemotherapeutic settings, which is important 
considering the recent reclassification in the guidelines of 
carboplatin AUC ≥ 415 and AC combination regimens to 
HEC.15-17
The high NSN rates are notable given the unmet clinical 
need for CINV prevention in the delayed setting, particularly 
for nausea control.26 Evidence from phase III studies of APR 
showed “no nausea” rates between 44% and 71%, and NSN 
rates between 57% and 78% in the delayed phase.27-31 A 
study of the NK1 RA rolapitant added to a granisetron‐DEX 
regimen reported no statistically significant improvement to 
nausea control in patients receiving AC and non‐AC HEC.32 
Another pooled analysis of 2 studies in patients receiv-
ing cisplatin‐based HEC reported statistically higher rates 
of NSN and “no nausea” in patients receiving rolapitant‐ 
granisetron‐DEX, compared with those receiving granisetron‐
DEX alone. However, when analyzed separately, 1 of the 2 trials 
showed no statistically significant difference in NSN rates.33 
Another study reported statistically significantly higher NSN 
but not “no nausea” rates in patients receiving rolapitant‐ 
ondansetron‐DEX compared with ondansetron‐DEX with 
cisplatin‐based HEC.34
Each of the 2 studies in this analysis reported more than 3‐
quarters of patients evaluable at the end of cycle 4. This is in 
contrast to other studies investigating antiemetic usage across 
multiple cycles. A recent post‐hoc analysis of pooled efficacy 
data from 4 trials of rolapitant presenting data from 2637 pa-
tients undergoing up to 6 cycles of chemotherapy reported 
that only ~50% completed cycle 4.35 Other multiple‐cycle tri-
als of antiemetics also reported high dropout rates, which has 
hampered the interpretation of results in these studies.36-40 
Despite NEPA's sustained efficacy over multiple cycles re-
ported in the present analysis, there are limitations to our 
methodology. The 2 studies were sufficiently heterogeneous, 
preventing pooled analysis, and the main focus of Study 2 
was on safety, hence not designed to formally compare the 
efficacy of oral NEPA with an APR triplet (the APR‐PALO 
arm was included only as a safety reference). Furthermore, 
the increased percentage of patients in both studies with CR 
and NSN in subsequent cycles may reflect a selection bias 
in which responders, but not nonresponders, preferentially 
continued to receive further cycles. In the subset of patients 
treated with MEC, 60% of patients received carboplatin. It is 
noteworthy that carboplatin was considered as MEC by all 
guidelines at the time the study was conducted; however, all 
guidelines currently recommend antiemetics consistent with 
those administered for HEC in patients receiving carboplatin 
AUC ≥ 4 mg mL−1 min.
In conclusion, oral NEPA, the first antiemetic combination 
agent targeting 2 critical emetic pathways, demonstrated superi-
ority over PALO in terms of CR in all 3 phases of cycle 1 (Study 
1); also, NEPA resulted in high CR and NSN rates during the 
acute and delayed phases, as well as in the overall phase across 
the 4 cycles (Studies 1 and 2), regardless of whether patients 
were receiving an AC MEC, non‐AC MEC, or HEC regimen. 
F I G U R E  2  CR (no emesis, no rescue medication) rates in the 
delayed phase (>24‐120 h) of cycles 1‐4 in: A) Study 1 (patients 
receiving AC‐based chemotherapy), and B) Study 2 (patients receiving 
HEC or MECa). Full analysis set. aBreast cancer patients were not 
allowed AC‐based regimens. AC, anthracycline‐cyclophosphamide; 
APR, aprepitant; CR, complete response; HEC, highly emetogenic 
chemotherapy; MEC, moderately emetogenic chemotherapy; NEPA, 
netupitant‐palonosetron; PALO, palonosetron
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T A B L E  4  CR, no emesis, and NSN rates in the acute (0‐24 h) and delayed (>24‐120 h) phase of cycles 1‐4—full analysis set
Study 1 Cycle (N = NEPA/PALO)
Cycle 1 
(N = 724/725)
Cycle 2 
(N = 635/651)
Cycle 3 
(N = 598/606)
Cycle 4 
(N = 551/560)
CR Acute NEPA, % 88.4 89.9 91.6 91.5
PALO, % 85.0 83.7 83.8 86.8
P valuea 0.047 0.001 <0.001 0.011
Delayed NEPA, % 76.9 81.7 85.1 85.5
PALO, % 69.5 68.8 74.4 77.3
P valuea 0.001 <0.001 <0.001 <0.001
Overall NEPA, % 74.3 80.3 83.8 83.8
PALO, % 66.6 66.7 70.3 74.6
P valuea 0.001 <0.001 <0.001 <0.001
No emesis Acute NEPA, % 90.9 92.6 93.0 93.1
PALO, % 87.3 86.8 87.5 88.4
P valuea 0.025 <0.001 0.002 0.006
Delayed NEPA, % 81.8 86.3 89.5 88.8
PALO, % 75.6 76.5 81.0 82.3
P valuea 0.004 <0.001 <0.001 0.002
Overall NEPA, % 79.8 85.5 88.3 87.3
PALO, % 72.1 73.7 77.2 79.5
P valuea <0.001 <0.001 <0.001 <0.001
NSNb Acute NEPA, % 87.3 88.8 89.1 91.3
PALO, % 87.9 87.3 87.1 88.9
P value 0.747 0.431 0.297 0.181
Delayed NEPA, % 76.9 79.5 79.8 81.7
PALO, % 71.3 74.0 75.4 76.4
P valuea 0.014 0.017 0.062 0.025
Overall NEPA, % 74.6 77.3 78.4 80.2
PALO, % 69.1 71.6 73.3 75.2
P valuea 0.020 0.016 0.033 0.035
Study 2 Cycle (N = NEPA/APR + PALO)
Cycle 1 
(N = 309/103)
Cycle 2 
(N = 280/96)
Cycle 3 
(N = 259/90)
Cycle 4 
(N = 233/81)
CR Acute NEPA, % 92.9 96.4 96.1 96.6
APR + PALO, % 94.2 91.7 95.6 96.3
Delayed NEPA, % 83.2 86.8 91.5 91.0
APR + PALO, % 77.7 82.3 87.8 87.7
Overall NEPA, % 80.6 86.1 90.7 90.1
APR + PALO, % 75.7 81.3 86.7 87.7
NSNb Acute NEPA, % 90.6 95.4 96.1 97.0
APR + PALO, % 93.2 92.7 93.3 95.1
Delayed NEPA, % 85.1 87.5 90.0 91.8
APR + PALO, % 81.6 86.5 84.4 86.4
Overall NEPA, % 84.1 86.8 89.6 91.8
APR + PALO, % 80.6 86.5 83.3 86.4
APR, aprepitant; CR, complete response; NEPA, netupitant‐palonosetron; NSN, no significant nausea; PALO, palonosetron; VAS, visual analog scale.
aTest prespecified and adjusted for multiplicity for CR at cycle 1 only; post‐hoc for cycles 2‐4 (not adjusted for multiplicity). 
bDefined as maximum daily nausea score <25 mm on 100‐mm VAS. 
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Preservation of the antiemetic effect of oral NEPA over mul-
tiple cycles suggests the utility of this agent in providing sus-
tained CINV control beyond the first cycle. The convenient 
fixed single‐dose, once‐per‐cycle administration of oral NEPA 
may improve adherence to antiemetic guidelines and increase 
treatment compliance, hence improve CINV prevention; this 
will need to be verified in prospective studies.
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